S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
Indiana secretary of state appeals ruling for US Senate candidate seeking GOP nod
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is carbon capture and why does it keep coming up at COP28?
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
All the trading advice you’ve ever received boils down to this (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Consumer product agency issues warning on small magnetic balls linked to deaths
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
Indiana secretary of state appeals ruling for US Senate candidate seeking GOP nod
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is carbon capture and why does it keep coming up at COP28?
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
All the trading advice you’ve ever received boils down to this (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Consumer product agency issues warning on small magnetic balls linked to deaths
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
Indiana secretary of state appeals ruling for US Senate candidate seeking GOP nod
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is carbon capture and why does it keep coming up at COP28?
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
All the trading advice you’ve ever received boils down to this (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Consumer product agency issues warning on small magnetic balls linked to deaths
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
Indiana secretary of state appeals ruling for US Senate candidate seeking GOP nod
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is carbon capture and why does it keep coming up at COP28?
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
All the trading advice you’ve ever received boils down to this (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Consumer product agency issues warning on small magnetic balls linked to deaths

AzurRx BioPharma Stock Price, News & Analysis (NASDAQ:AZRX)

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$0.30
$0.33
50-Day Range
$2.40
$41.00
52-Week Range
$3.36
$26.30
Volume
187,726 shs
Average Volume
628,703 shs
Market Capitalization
$3.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

AZRX stock logo

About AzurRx BioPharma Stock (NASDAQ:AZRX)

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.


AZRX Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
FWBI First Wave BioPharma, Inc.
First Wave BioPharma Inc (FWBI)
First Wave BioPharma Inc
AzurRx BioPharma Changes Name to First Wave BioPharma
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
AzurRx (AZRX) Announces First Wave Bio Acquisition for $229M
AzurRx BioPharma To Acquire First Wave Bio For $229M
AzurRx BioPharma Announces Reverse Stock Split
See More Headlines
Receive AZRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AzurRx BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
12/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AZRX
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

Net Income
$-32,670,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.76) per share

Miscellaneous

Free Float
8,645,000
Market Cap
$3.03 million
Optionable
Not Optionable
Beta
1.51
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • James E. Sapirstein
    Chairman, President & Chief Executive Officer
  • Daniel H. Schneiderman
    Chief Financial Officer
  • James E. Pennington
    Chief Medical Officer
  • Tony Baca
    Vice President-Clinical Operations
  • Martin Krusin
    Senior Vice President-Corporate Development














AZRX Stock Analysis - Frequently Asked Questions

When did AzurRx BioPharma's stock split?

Shares of AzurRx BioPharma reverse split on Monday, September 13th 2021. The 1-10 reverse split was announced on Monday, September 13th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 13th 2021. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of AzurRx BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AzurRx BioPharma investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), SCYNEXIS (SCYX), Gran Tierra Energy (GTE), Cogent Biosciences (UMRX), KushCo (KSHB), Organigram (OGI), Pennsylvania Real Estate Investment Trust (PEI) and Novan (NOVN).

When did AzurRx BioPharma IPO?

(AZRX) raised $15 million in an IPO on Friday, September 9th 2016. The company issued 2,100,000 shares at a price of $6.00-$8.00 per share. WallachBeth Capital and Network 1 Financial Securities served as the underwriters for the IPO.

This page (NASDAQ:AZRX) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -